
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings is poised for success in the oncology, infectious disease, and autoimmune markets with a deep pipeline and commercially successful KIMMTRAK product. The company's unique ImmTAX platform, which includes Brenetafusp and other candidates, has shown promise in 5-year survival data, with a 16% rate compared to just 8% in the control arm with investigator's choice. Additionally, with the potential approval of KIMMTRAK for cutaneous melanoma, there is significant upside for the stock in the future.
Bears say
Immunocore Holdings is facing several challenges ahead despite its current success, including potential slow growth in 2026 due to saturation in major markets and increased competition in its pipeline, as well as no guarantee of success in its ongoing clinical programs. Additionally, the company's decision not to expand KIMMTRAK to other HLA types may limit its potential market size and revenues. While Immunocore's current financials look promising, it is important to closely monitor its future developments and address these concerns to formulate a more positive outlook on the company's stock.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares